13856 research outputs found
Sort by
[[alternative]]PTGR2 inhibitors and their use
No full text[[abstract]]本揭露提供一種如下式(I)之化合物：其中，R1、R2、R3、R4、R5、L1、W和Het各自在本文中定義。本揭露還提供了一種使用這種化合物來抑制前列腺素還原酶2(PTGR2)的方法以及含有該化合物的醫藥組成物
阿片受體調節劑及其用途
No full text[[abstract]]公開了用於鑒定μ ‑阿片受體的拮抗劑‑轉‑激動劑的變構調節劑的體外篩選方法，以及用於確認測試化合物為這樣的μ ‑阿片受體的調節劑的體內方法。還公開了使用式（I）的化合物治療阿片受體相關病症的方法以及包含此化合物的藥物組合物
Opioid receptor modulators and use thereof
No full text[[abstract]]Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same
[[alternative]]Inhibitors of positive strand RNA viruses
No full text[[abstract]]本發明係關於化合物之用途，其係用於製備治療正股核糖核酸病毒引起的疾病之醫藥組成物，該醫藥組成物包括一有效量的一式I或式II化合物及一醫藥上可接受之載體
[[alternative]]Methods of increasing cell phagocytosis
No full text[[abstract]]本揭露使用式(I)化合物治療涉及CD47正向調控的病症之方法：變數R1-R9、X及Het定義於內文中。還揭露了使用這種化合物及各自含有該化合物和抗癌藥物之醫藥組合物用於增加細胞吞噬作用之方法
氨基噻唑化合物及其用途
No full text[[abstract]]本发明提供本文所示的式(I)的氨基噻唑化合物及包含此类化合物中的一种的药物组合物。本发明还公开分别使用所述氨基噻唑化合物中的一种来抑制蛋白激酶或治疗与蛋白激酶相关的癌症的多种方法
CDGSH iron sulfur domain 2 activators and use thereof
No full text[[abstract]]Isoindoline compounds and their pharmaceutical compositions. Also provided are methods of treating a Cisd2-insufficiency associated disorder and protecting against doxorubicin-induced cardiotoxicity
Identifying serum biomarkers for predicting the resistance of enzalutamide or abiraterone in prostate cancer patients
No full text[[abstract]]Abiraterone acetate and enzalutamide are useand can increase the life span of CRPC patients for a few months. However, approximately 40% of patients do not respond to treatment with enzalutamide or abiraterone and the majority of patients who initially respond will eventually develop drug resistance. Currently there is no examination to assist the clinician doctors to decide the optimal drug for individual patient. Micro-Western Array (MWA) is a high-throughput antibody-based proteomics system which allows detection of the expression of 24-96 different proteins within 6-30 samples simultaneously. We applied MWA to examine the difference of serum protein profile in CRPC patients before and during the treatment with enzalutamide or abiraterone. The profile of proteins in patients who responded to treatment was significantly different from that in patients with drug resistance. The profile in enzalutamide-resistant patients was also different from that in abiraterone-resistant patients. We identified a set of serum proteins which are promising biomarkers to predict if the patients will respond to treatment with enzalutamide or abiraterone
[[alternative]]Incorporation of 198Au into Gold Nanoparticles for Concurrent Chemoradiotherapy in Glioblastoma-bearing Xenografts
No full text[[abstract]]The 198Au (half-life: 2.69 days) is a manufactured radioactive isotope that irradiates gamma photons (Eγ: 412 keV) and beta particles (Eβmax: 0.96 MeV ). This study demonstrates a one-pot/one-step to synthesize radioactive gold nanoparticles (RGNP)without using radioactive precursors and reducing agents. The precursor solution of gold ions is reduced into gold nanoparticles (size: 8.6-146 nm), and a particular portion of 197Au is converted to198Au, rendering the nanoparticles radioactive. Furthermore, we suggest using a combination of RGNP applied through convection-enhanced delivery (CED) and temozolomide (TMZ) through oral administration to treat glioblastoma-bearing xenografts. The mean survival for RGNP/TMZ treatment was (68.9±9.7 days) compared to that for standalone RGNP (38.4±2.2 days) or TMZ (42.8±2.5 days) therapies. Based on the verification of bioluminescence images (BLI), positron emission tomography (PET), and immunohistochemistry (IHC) inspection, the combination treatment demonstrates concurrent chemoradiotherapy(CCRT) of RGNP/TMZ successfully inhibiting the proliferation of glioblastoma
